Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection
Identifieur interne : 001109 ( Istex/Corpus ); précédent : 001108; suivant : 001110Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection
Auteurs : Daisuke Ikeno ; Kazuhiko Kimachi ; Yoichiro Kino ; Seiichi Harada ; Kayo Yoshida ; Shinji Tochihara ; Shigeyuki Itamura ; Takato Odagiri ; Masato Tashiro ; Kenji Okada ; Chiaki Miyazaki ; Kohji UedaSource :
- Microbiology and Immunology [ 0385-5600 ] ; 2010-02.
English descriptors
- Teeft :
- Adjuvant, Administration route, Administration routes, Adverse events, Alum, Alum adjuvant, Aluminum hydroxide, Antibody titer, Antibody titers, Blackwell publishing asia, Cell culture, Chmp criteria, Clinical study, Clinical trial, Dos, Erythema, European union chmp criteria, Healthy adults, Healthy japanese, Horse erythrocytes, Immune, Immune response, Immune responses, Immunogenicity, Induration pruritus pyrexia headache malaise chill diarrhea, Infectious diseases, Injection, Kawabe kyokushi, Kikuchi research center, Microbiol immunol, More immunogenic, National institute, Pain erythema, Pandemic, Pruritus, Randomised trial, Research institute, Seasonal vaccines, Second dose, Second doses, Seroconversion, Seroconversion factor, Seroconversion factor seropositivity seroconversion, Serum samples, Statistical analysis, Subcutaneous injection, Titer, Vaccination, Vaccine, Whole virion vaccine.
Abstract
The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.
Url:
DOI: 10.1111/j.1348-0421.2009.00191.x
Links to Exploration step
ISTEX:D8C94B5A650C9D8C073F65103101A6486AC3A45ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title><author><name sortKey="Ikeno, Daisuke" sort="Ikeno, Daisuke" uniqKey="Ikeno D" first="Daisuke" last="Ikeno">Daisuke Ikeno</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Kimachi, Kazuhiko" sort="Kimachi, Kazuhiko" uniqKey="Kimachi K" first="Kazuhiko" last="Kimachi">Kazuhiko Kimachi</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Kino, Yoichiro" sort="Kino, Yoichiro" uniqKey="Kino Y" first="Yoichiro" last="Kino">Yoichiro Kino</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Harada, Seiichi" sort="Harada, Seiichi" uniqKey="Harada S" first="Seiichi" last="Harada">Seiichi Harada</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Yoshida, Kayo" sort="Yoshida, Kayo" uniqKey="Yoshida K" first="Kayo" last="Yoshida">Kayo Yoshida</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Tochihara, Shinji" sort="Tochihara, Shinji" uniqKey="Tochihara S" first="Shinji" last="Tochihara">Shinji Tochihara</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Itamura, Shigeyuki" sort="Itamura, Shigeyuki" uniqKey="Itamura S" first="Shigeyuki" last="Itamura">Shigeyuki Itamura</name><affiliation><mods:affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</mods:affiliation></affiliation></author><author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name><affiliation><mods:affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</mods:affiliation></affiliation></author><author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name><affiliation><mods:affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</mods:affiliation></affiliation></author><author><name sortKey="Okada, Kenji" sort="Okada, Kenji" uniqKey="Okada K" first="Kenji" last="Okada">Kenji Okada</name><affiliation><mods:affiliation>Section of Pediatrics, Fukuoka National Hospital, 4‐39‐1 Yakatabaru, Minami‐ku, Fukuoka, 811‐1394</mods:affiliation></affiliation></author><author><name sortKey="Miyazaki, Chiaki" sort="Miyazaki, Chiaki" uniqKey="Miyazaki C" first="Chiaki" last="Miyazaki">Chiaki Miyazaki</name><affiliation><mods:affiliation>Fukuoka‐West Rehabilitation Center, Fukuoka, Fukuoka 819‐0005</mods:affiliation></affiliation></author><author><name sortKey="Ueda, Kohji" sort="Ueda, Kohji" uniqKey="Ueda K" first="Kohji" last="Ueda">Kohji Ueda</name><affiliation><mods:affiliation>Faculty of Health and Welfare, Seinan Jo Gakuin University, 1‐3‐5 Ibori Kokurakitaku, Kitakyusyu 803‐0835, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8C94B5A650C9D8C073F65103101A6486AC3A45E</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1348-0421.2009.00191.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-39NGXXSL-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001109</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001109</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title><author><name sortKey="Ikeno, Daisuke" sort="Ikeno, Daisuke" uniqKey="Ikeno D" first="Daisuke" last="Ikeno">Daisuke Ikeno</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Kimachi, Kazuhiko" sort="Kimachi, Kazuhiko" uniqKey="Kimachi K" first="Kazuhiko" last="Kimachi">Kazuhiko Kimachi</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Kino, Yoichiro" sort="Kino, Yoichiro" uniqKey="Kino Y" first="Yoichiro" last="Kino">Yoichiro Kino</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Harada, Seiichi" sort="Harada, Seiichi" uniqKey="Harada S" first="Seiichi" last="Harada">Seiichi Harada</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Yoshida, Kayo" sort="Yoshida, Kayo" uniqKey="Yoshida K" first="Kayo" last="Yoshida">Kayo Yoshida</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Tochihara, Shinji" sort="Tochihara, Shinji" uniqKey="Tochihara S" first="Shinji" last="Tochihara">Shinji Tochihara</name><affiliation><mods:affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</mods:affiliation></affiliation></author><author><name sortKey="Itamura, Shigeyuki" sort="Itamura, Shigeyuki" uniqKey="Itamura S" first="Shigeyuki" last="Itamura">Shigeyuki Itamura</name><affiliation><mods:affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</mods:affiliation></affiliation></author><author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name><affiliation><mods:affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</mods:affiliation></affiliation></author><author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name><affiliation><mods:affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</mods:affiliation></affiliation></author><author><name sortKey="Okada, Kenji" sort="Okada, Kenji" uniqKey="Okada K" first="Kenji" last="Okada">Kenji Okada</name><affiliation><mods:affiliation>Section of Pediatrics, Fukuoka National Hospital, 4‐39‐1 Yakatabaru, Minami‐ku, Fukuoka, 811‐1394</mods:affiliation></affiliation></author><author><name sortKey="Miyazaki, Chiaki" sort="Miyazaki, Chiaki" uniqKey="Miyazaki C" first="Chiaki" last="Miyazaki">Chiaki Miyazaki</name><affiliation><mods:affiliation>Fukuoka‐West Rehabilitation Center, Fukuoka, Fukuoka 819‐0005</mods:affiliation></affiliation></author><author><name sortKey="Ueda, Kohji" sort="Ueda, Kohji" uniqKey="Ueda K" first="Kohji" last="Ueda">Kohji Ueda</name><affiliation><mods:affiliation>Faculty of Health and Welfare, Seinan Jo Gakuin University, 1‐3‐5 Ibori Kokurakitaku, Kitakyusyu 803‐0835, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Microbiology and Immunology</title><title level="j" type="alt">MICROBIOLOGY IMMUNOLOGY</title><idno type="ISSN">0385-5600</idno><idno type="eISSN">1348-0421</idno><imprint><biblScope unit="vol">54</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="81">81</biblScope><biblScope unit="page" to="88">88</biblScope><biblScope unit="page-count">8</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2010-02">2010-02</date></imprint><idno type="ISSN">0385-5600</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0385-5600</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Administration route</term><term>Administration routes</term><term>Adverse events</term><term>Alum</term><term>Alum adjuvant</term><term>Aluminum hydroxide</term><term>Antibody titer</term><term>Antibody titers</term><term>Blackwell publishing asia</term><term>Cell culture</term><term>Chmp criteria</term><term>Clinical study</term><term>Clinical trial</term><term>Dos</term><term>Erythema</term><term>European union chmp criteria</term><term>Healthy adults</term><term>Healthy japanese</term><term>Horse erythrocytes</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunogenicity</term><term>Induration pruritus pyrexia headache malaise chill diarrhea</term><term>Infectious diseases</term><term>Injection</term><term>Kawabe kyokushi</term><term>Kikuchi research center</term><term>Microbiol immunol</term><term>More immunogenic</term><term>National institute</term><term>Pain erythema</term><term>Pandemic</term><term>Pruritus</term><term>Randomised trial</term><term>Research institute</term><term>Seasonal vaccines</term><term>Second dose</term><term>Second doses</term><term>Seroconversion</term><term>Seroconversion factor</term><term>Seroconversion factor seropositivity seroconversion</term><term>Serum samples</term><term>Statistical analysis</term><term>Subcutaneous injection</term><term>Titer</term><term>Vaccination</term><term>Vaccine</term><term>Whole virion vaccine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>immunogenicity</json:string><json:string>adjuvant</json:string><json:string>adverse events</json:string><json:string>alum adjuvant</json:string><json:string>seroconversion</json:string><json:string>second dose</json:string><json:string>erythema</json:string><json:string>clinical study</json:string><json:string>blackwell publishing asia</json:string><json:string>immune</json:string><json:string>pruritus</json:string><json:string>alum</json:string><json:string>immune response</json:string><json:string>research institute</json:string><json:string>clinical trial</json:string><json:string>dos</json:string><json:string>horse erythrocytes</json:string><json:string>pain erythema</json:string><json:string>induration pruritus pyrexia headache malaise chill diarrhea</json:string><json:string>pandemic</json:string><json:string>more immunogenic</json:string><json:string>aluminum hydroxide</json:string><json:string>national institute</json:string><json:string>serum samples</json:string><json:string>chmp criteria</json:string><json:string>titer</json:string><json:string>cell culture</json:string><json:string>kikuchi research center</json:string><json:string>kawabe kyokushi</json:string><json:string>administration route</json:string><json:string>statistical analysis</json:string><json:string>european union chmp criteria</json:string><json:string>seasonal vaccines</json:string><json:string>healthy japanese</json:string><json:string>second doses</json:string><json:string>infectious diseases</json:string><json:string>whole virion vaccine</json:string><json:string>microbiol immunol</json:string><json:string>seroconversion factor</json:string><json:string>subcutaneous injection</json:string><json:string>administration routes</json:string><json:string>antibody titers</json:string><json:string>seroconversion factor seropositivity seroconversion</json:string><json:string>antibody titer</json:string><json:string>immune responses</json:string><json:string>randomised trial</json:string><json:string>healthy adults</json:string><json:string>vaccination</json:string><json:string>injection</json:string></teeft></keywords><author><json:item><name>Daisuke Ikeno</name><affiliations><json:string>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</json:string></affiliations></json:item><json:item><name>Kazuhiko Kimachi</name><affiliations><json:string>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</json:string></affiliations></json:item><json:item><name>Yoichiro Kino</name><affiliations><json:string>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</json:string></affiliations></json:item><json:item><name>Seiichi Harada</name><affiliations><json:string>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</json:string></affiliations></json:item><json:item><name>Kayo Yoshida</name><affiliations><json:string>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</json:string></affiliations></json:item><json:item><name>Shinji Tochihara</name><affiliations><json:string>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</json:string></affiliations></json:item><json:item><name>Shigeyuki Itamura</name><affiliations><json:string>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</json:string></affiliations></json:item><json:item><name>Takato Odagiri</name><affiliations><json:string>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</json:string></affiliations></json:item><json:item><name>Masato Tashiro</name><affiliations><json:string>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</json:string></affiliations></json:item><json:item><name>Kenji Okada</name><affiliations><json:string>Section of Pediatrics, Fukuoka National Hospital, 4‐39‐1 Yakatabaru, Minami‐ku, Fukuoka, 811‐1394</json:string></affiliations></json:item><json:item><name>Chiaki Miyazaki</name><affiliations><json:string>Fukuoka‐West Rehabilitation Center, Fukuoka, Fukuoka 819‐0005</json:string></affiliations></json:item><json:item><name>Kohji Ueda</name><affiliations><json:string>Faculty of Health and Welfare, Seinan Jo Gakuin University, 1‐3‐5 Ibori Kokurakitaku, Kitakyusyu 803‐0835, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>influenza</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>intramuscular injection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pandemic</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>subcutaneous injection</value></json:item></subject><articleId><json:string>MIM191</json:string></articleId><arkIstex>ark:/67375/WNG-39NGXXSL-5</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.</abstract><qualityIndicators><score>7.869</score><pdfWordCount>4585</pdfWordCount><pdfCharCount>27958</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>595 x 779.6 pts</pdfPageSize><pdfWordsPerPage>573</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>107</abstractWordCount><abstractCharCount>691</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title><pmid><json:string>20377741</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Microbiology and Immunology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1348-0421</json:string></doi><issn><json:string>0385-5600</json:string></issn><eissn><json:string>1348-0421</json:string></eissn><publisherId><json:string>MIM</json:string></publisherId><volume>54</volume><issue>2</issue><pages><first>81</first><last>88</last><total>8</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2009</json:string><json:string>1-3-5</json:string><json:string>2003</json:string><json:string>from January 2007 to April 2007</json:string><json:string>4-7-1</json:string><json:string>2010</json:string></date><geogName></geogName><orgName><json:string>Good Laboratory Practice</json:string><json:string>WHO</json:string><json:string>Blackwell Publishing Asia Pty Ltd</json:string><json:string>Japan ABSTRACT The</json:string><json:string>American Academy of Pediatrics</json:string><json:string>National Institute of Infectious Diseases, Gakuen</json:string><json:string>Chemo-Sero-Therapeutic Research Institute</json:string><json:string>UK NIBSC</json:string><json:string>Medical Corporation Kouryokai</json:string><json:string>Egypt, China, and Vietnam</json:string><json:string>Seinan Jo Gakuin University</json:string><json:string>Fukuoka National Hospital</json:string><json:string>Chemo-Sero-Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto</json:string><json:string>European Medicine Agency</json:string><json:string>Blackwell Publishing Asia Pty</json:string><json:string>National Institute for Biological Standards and Control</json:string><json:string>National Institute of Infectious Diseases</json:string><json:string>Fukuoka-West Rehabilitation Center, Fukuoka, Fukuoka</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Hong Kong</json:string><json:string>Yuki Ito</json:string><json:string>Naoko</json:string><json:string>Michael Leoncavallo</json:string></persName><placeName><json:string>Fukuoka</json:string><json:string>Vietnam</json:string><json:string>Bar</json:string><json:string>UK</json:string><json:string>Kumamoto</json:string><json:string>Japan</json:string><json:string>Miyazaki</json:string><json:string>Puri</json:string><json:string>Tokyo</json:string><json:string>European Union</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[28]</json:string><json:string>[27]</json:string><json:string>D. Ikeno et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-39NGXXSL-5</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Microbiology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pathologie infectieuse</json:string></inist></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1111/j.1348-0421.2009.00191.x</json:string></doi><id>D8C94B5A650C9D8C073F65103101A6486AC3A45E</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-39NGXXSL-5/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-39NGXXSL-5/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-39NGXXSL-5/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title><title level="a" type="short">Influenza A (H5N1) vaccine</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><availability><licence>© 2009 The Societies and Blackwell Publishing Asia Pty Ltd</licence></availability><date type="published" when="2010-02"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title><title level="a" type="short">Influenza A (H5N1) vaccine</title><author xml:id="author-0000"><persName><forename type="first">Daisuke</forename><surname>Ikeno</surname></persName><affiliation><orgName type="institution">The Chemo‐Sero‐Therapeutic Research Institute</orgName><orgName type="institution">Kikuchi Research Center</orgName><address><addrLine>Kawabe Kyokushi</addrLine><addrLine>Kikuchi, Kumamoto 869‐1298</addrLine></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Kazuhiko</forename><surname>Kimachi</surname></persName><affiliation><orgName type="institution">The Chemo‐Sero‐Therapeutic Research Institute</orgName><orgName type="institution">Kikuchi Research Center</orgName><address><addrLine>Kawabe Kyokushi</addrLine><addrLine>Kikuchi, Kumamoto 869‐1298</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Yoichiro</forename><surname>Kino</surname></persName><affiliation><orgName type="institution">The Chemo‐Sero‐Therapeutic Research Institute</orgName><orgName type="institution">Kikuchi Research Center</orgName><address><addrLine>Kawabe Kyokushi</addrLine><addrLine>Kikuchi, Kumamoto 869‐1298</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Seiichi</forename><surname>Harada</surname></persName><affiliation><orgName type="institution">The Chemo‐Sero‐Therapeutic Research Institute</orgName><orgName type="institution">Kikuchi Research Center</orgName><address><addrLine>Kawabe Kyokushi</addrLine><addrLine>Kikuchi, Kumamoto 869‐1298</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Kayo</forename><surname>Yoshida</surname></persName><affiliation><orgName type="institution">The Chemo‐Sero‐Therapeutic Research Institute</orgName><orgName type="institution">Kikuchi Research Center</orgName><address><addrLine>Kawabe Kyokushi</addrLine><addrLine>Kikuchi, Kumamoto 869‐1298</addrLine></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Shinji</forename><surname>Tochihara</surname></persName><affiliation><orgName type="institution">The Chemo‐Sero‐Therapeutic Research Institute</orgName><orgName type="institution">Kikuchi Research Center</orgName><address><addrLine>Kawabe Kyokushi</addrLine><addrLine>Kikuchi, Kumamoto 869‐1298</addrLine></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Shigeyuki</forename><surname>Itamura</surname></persName><affiliation><orgName type="institution">National Institute of Infectious Diseases</orgName><address><addrLine>Gakuen 4‐7‐1</addrLine><addrLine>Musashi‐Murayama, Tokyo 208‐0011</addrLine></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Takato</forename><surname>Odagiri</surname></persName><affiliation><orgName type="institution">National Institute of Infectious Diseases</orgName><address><addrLine>Gakuen 4‐7‐1</addrLine><addrLine>Musashi‐Murayama, Tokyo 208‐0011</addrLine></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Masato</forename><surname>Tashiro</surname></persName><affiliation><orgName type="institution">National Institute of Infectious Diseases</orgName><address><addrLine>Gakuen 4‐7‐1</addrLine><addrLine>Musashi‐Murayama, Tokyo 208‐0011</addrLine></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">Kenji</forename><surname>Okada</surname></persName><affiliation><orgName type="division">Section of Pediatrics</orgName><orgName type="institution">Fukuoka National Hospital</orgName><address><addrLine>4‐39‐1 Yakatabaru</addrLine><addrLine>Minami‐ku, Fukuoka, 811‐1394</addrLine></address></affiliation></author><author xml:id="author-0010"><persName><forename type="first">Chiaki</forename><surname>Miyazaki</surname></persName><affiliation><orgName type="institution">Fukuoka‐West Rehabilitation Center</orgName><address><addrLine>Fukuoka</addrLine><addrLine>Fukuoka 819‐0005</addrLine></address></affiliation></author><author xml:id="author-0011"><persName><forename type="first">Kohji</forename><surname>Ueda</surname></persName><affiliation><orgName type="department">Faculty of Health and Welfare</orgName><orgName type="institution">Seinan Jo Gakuin University</orgName><address><addrLine>1‐3‐5 Ibori Kokurakitaku</addrLine><addrLine>Kitakyusyu 803‐0835, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><idno type="istex">D8C94B5A650C9D8C073F65103101A6486AC3A45E</idno><idno type="ark">ark:/67375/WNG-39NGXXSL-5</idno><idno type="DOI">10.1111/j.1348-0421.2009.00191.x</idno><idno type="unit">MIM191</idno><idno type="toTypesetVersion">file:MIM.MIM191.pdf</idno></analytic><monogr><title level="j" type="main">Microbiology and Immunology</title><title level="j" type="alt">MICROBIOLOGY IMMUNOLOGY</title><idno type="pISSN">0385-5600</idno><idno type="eISSN">1348-0421</idno><idno type="book-DOI">10.1111/(ISSN)1348-0421</idno><idno type="book-part-DOI">10.1111/mim.2010.54.issue-2</idno><idno type="product">MIM</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">54</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="81">81</biblScope><biblScope unit="page" to="88">88</biblScope><biblScope unit="page-count">8</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2010-02"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>ABSTRACT</head><p>The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">influenza</term><term xml:id="k2">intramuscular injection</term><term xml:id="k3">pandemic</term><term xml:id="k4">subcutaneous injection</term></keywords><keywords rend="tocHeading1"><term>Original articles</term></keywords><keywords rend="tocHeading2"><term>Virology</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-39NGXXSL-5/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Asia</publisherName><publisherLoc>Melbourne, Australia</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1348-0421</doi><issn type="print">0385-5600</issn><issn type="electronic">1348-0421</issn><idGroup><id type="product" value="MIM"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="MICROBIOLOGY IMMUNOLOGY">Microbiology and Immunology</title></titleGroup></publicationMeta><publicationMeta level="part" position="02002"><doi origin="wiley">10.1111/mim.2010.54.issue-2</doi><numberingGroup><numbering type="journalVolume" number="54">54</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="2010-02">February 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="3" status="forIssue"><doi origin="wiley">10.1111/j.1348-0421.2009.00191.x</doi><idGroup><id type="unit" value="MIM191"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="tocHeading1">Original articles</title><title type="tocHeading2">Virology</title></titleGroup><copyright>© 2009 The Societies and Blackwell Publishing Asia Pty Ltd</copyright><eventGroup><event type="firstOnline" date="2009-11-20"></event><event type="publishedOnlineFinalForm" date="2010-01-25"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.4 mode:FullText source:FullText result:FullText" date="2010-03-29"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="81">81</numbering><numbering type="pageLast" number="88">88</numbering></numberingGroup><correspondenceTo><b>Correspondence</b>
Daisuke Ikeno, The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298, Japan.
Tel: +81 968 37 4090; fax: +81 968 37 3616; email: <email normalForm="ikeno-da@kaketsuken.or.jp">ikeno‐da@kaketsuken.or.jp</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MIM.MIM191.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 29 August 2009; revised 27 October 2009; accepted 28 October 2009.</unparsedEditorialHistory><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="28"></count><count type="linksCrossRef" number="48"></count></countGroup><titleGroup><title type="main">Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title><title type="shortAuthors">D. Ikeno <i>et al.</i></title><title type="short">Influenza A (H5N1) vaccine</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Daisuke</givenNames><familyName>Ikeno</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Kazuhiko</givenNames><familyName>Kimachi</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Yoichiro</givenNames><familyName>Kino</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>Seiichi</givenNames><familyName>Harada</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1"><personName><givenNames>Kayo</givenNames><familyName>Yoshida</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>Shinji</givenNames><familyName>Tochihara</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a2"><personName><givenNames>Shigeyuki</givenNames><familyName>Itamura</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a2"><personName><givenNames>Takato</givenNames><familyName>Odagiri</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a2"><personName><givenNames>Masato</givenNames><familyName>Tashiro</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a3"><personName><givenNames>Kenji</givenNames><familyName>Okada</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a4"><personName><givenNames>Chiaki</givenNames><familyName>Miyazaki</familyName></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#a5"><personName><givenNames>Kohji</givenNames><familyName>Ueda</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</unparsedAffiliation></affiliation><affiliation xml:id="a3"><unparsedAffiliation>Section of Pediatrics, Fukuoka National Hospital, 4‐39‐1 Yakatabaru, Minami‐ku, Fukuoka, 811‐1394</unparsedAffiliation></affiliation><affiliation xml:id="a4"><unparsedAffiliation>Fukuoka‐West Rehabilitation Center, Fukuoka, Fukuoka 819‐0005</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="JP"><unparsedAffiliation>Faculty of Health and Welfare, Seinan Jo Gakuin University, 1‐3‐5 Ibori Kokurakitaku, Kitakyusyu 803‐0835, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">influenza</keyword><keyword xml:id="k2">intramuscular injection</keyword><keyword xml:id="k3">pandemic</keyword><keyword xml:id="k4">subcutaneous injection</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">ABSTRACT</title><p>The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Influenza A (H5N1) vaccine</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection</title></titleInfo><name type="personal"><namePart type="given">Daisuke</namePart><namePart type="family">Ikeno</namePart><affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kazuhiko</namePart><namePart type="family">Kimachi</namePart><affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoichiro</namePart><namePart type="family">Kino</namePart><affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Seiichi</namePart><namePart type="family">Harada</namePart><affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kayo</namePart><namePart type="family">Yoshida</namePart><affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shinji</namePart><namePart type="family">Tochihara</namePart><affiliation>The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shigeyuki</namePart><namePart type="family">Itamura</namePart><affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Takato</namePart><namePart type="family">Odagiri</namePart><affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masato</namePart><namePart type="family">Tashiro</namePart><affiliation>National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kenji</namePart><namePart type="family">Okada</namePart><affiliation>Section of Pediatrics, Fukuoka National Hospital, 4‐39‐1 Yakatabaru, Minami‐ku, Fukuoka, 811‐1394</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chiaki</namePart><namePart type="family">Miyazaki</namePart><affiliation>Fukuoka‐West Rehabilitation Center, Fukuoka, Fukuoka 819‐0005</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kohji</namePart><namePart type="family">Ueda</namePart><affiliation>Faculty of Health and Welfare, Seinan Jo Gakuin University, 1‐3‐5 Ibori Kokurakitaku, Kitakyusyu 803‐0835, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Asia</publisher><place><placeTerm type="text">Melbourne, Australia</placeTerm></place><dateIssued encoding="w3cdtf">2010-02</dateIssued><edition>Received 29 August 2009; revised 27 October 2009; accepted 28 October 2009.</edition><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">3</extent><extent unit="formulas">0</extent><extent unit="references">28</extent><extent unit="linksCrossRef">48</extent></physicalDescription><abstract lang="en">The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.</abstract><subject lang="en"><genre>keywords</genre><topic>influenza</topic><topic>intramuscular injection</topic><topic>pandemic</topic><topic>subcutaneous injection</topic></subject><relatedItem type="host"><titleInfo><title>Microbiology and Immunology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0385-5600</identifier><identifier type="eISSN">1348-0421</identifier><identifier type="DOI">10.1111/(ISSN)1348-0421</identifier><identifier type="PublisherID">MIM</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>81</start><end>88</end><total>8</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO</title></titleInfo><name type="corporate"><namePart>WHO</namePart></name><genre>other</genre><part><date>2009</date></part></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre‐pandemic Vaccines</title></titleInfo><name type="corporate"><namePart>WHO</namePart></name><genre>other</genre><part><date>2009</date></part></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Tables on the Clinical trials of pandemic influenza prototype vaccines</title></titleInfo><name type="corporate"><namePart>WHO</namePart></name><genre>other</genre><part><date>2007</date></part></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Safety and efficacy of an inactivated whole‐virion influenza A (H5N1) vaccine</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Tashiro</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tashiro M. (2003) Safety and efficacy of an inactivated whole‐virion influenza A (H5N1) vaccine. MHLW Res: 200201019A (Japanese language only).</note><part><date>2003</date></part><relatedItem type="host"><titleInfo><title>MHLW Res</title></titleInfo><part><date>2003</date></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Immunogenicity of a monovalent, aluminum‐adjuvanted influenza whole virus vaccine for pandemic use</title></titleInfo><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Hehme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Engelmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Kuenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Neumeier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Saenger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hehme N., Engelmann H., Kuenzel W., Neumeier E., Saenger R. (2004) Immunogenicity of a monovalent, aluminum‐adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103: 163–71.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>163</start><end>71</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>163</start><end>71</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines</title></titleInfo><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Hehme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Engelmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Kunzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Neumeier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Sanger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hehme N., Engelmann H., Kunzel W., Neumeier E., Sanger R. (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191: 203–8.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>203</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Med Microbiol Immunol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>203</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Inactivated influenza H5N1 whole‐virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Ninomiya</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Imai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Tashiro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Odagiri</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ninomiya A., Imai M., Tashiro M., Odagiri T. (2007) Inactivated influenza H5N1 whole‐virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25: 3554–60.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3554</start><end>60</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3554</start><end>60</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults</title></titleInfo><name type="personal"><namePart type="given">I.F.</namePart><namePart type="family">Cook</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Barr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Hartel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Pond</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.W.</namePart><namePart type="family">Hampson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cook I.F., Barr I., Hartel G., Pond D., Hampson A.W. (2006) Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 24: 2395–402.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>2395</start><end>402</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>2395</start><end>402</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>American Academy of Pediatrics. (1997) RED BOOK, 24th Edition (ISBN: 0‐910761‐85‐x). p14.</title></titleInfo><name type="corporate"><namePart>American Academy of Pediatrics</namePart></name><genre>other</genre><part><date>1997</date></part></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Detection of anti‐H5 responses in human sera by HI using horse erythrocytes following MF59‐adjuvanted influenza A/Duck/Singapore/97 vaccine</title></titleInfo><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Stephenson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Wood</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.G.</namePart><namePart type="family">Nicholson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Charlett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.C.</namePart><namePart type="family">Zambon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stephenson I., Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. (2004) Detection of anti‐H5 responses in human sera by HI using horse erythrocytes following MF59‐adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91–5.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>91</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>91</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96)</title></titleInfo><name type="corporate"><namePart>European Medicine Agency</namePart></name><genre>other</genre><part><date>1997</date></part></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Safety and immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1) vaccine: a phase I randomised controlled trial</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Dong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Fang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Su</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Gao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z.</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z.</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Sun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Ji</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wood</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z.</namePart><namePart type="family">Feng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Yin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y., Wang Z., Yang M., Sun R., Li C., Lin S., Ji M., Liu Y., Wang X., Wood J., Feng Z., Wang Y., Yin W. (2006) Safety and immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991–7.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>368</number></detail><extent unit="pages"><start>991</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>368</number></detail><extent unit="pages"><start>991</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine</title></titleInfo><name type="personal"><namePart type="given">J.J.</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.D.</namePart><namePart type="family">Campbell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.M.</namePart><namePart type="family">Zangwill</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Rowe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Wolff</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343–51.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>354</number></detail><extent unit="pages"><start>1343</start><end>51</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>354</number></detail><extent unit="pages"><start>1343</start><end>51</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Safety and immunogenicity of an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial</title></titleInfo><name type="personal"><namePart type="given">J.L.</namePart><namePart type="family">Bresson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Perronne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Launay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Gerdil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Saville</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wood</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Hoschler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.C.</namePart><namePart type="family">Zambon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., Hoschler K., Zambon M.C. (2006) Safety and immunogenicity of an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657–64.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>367</number></detail><extent unit="pages"><start>1657</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>367</number></detail><extent unit="pages"><start>1657</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>A clinical trial of a whole‐virus H5N1 vaccine derived from cell culture</title></titleInfo><name type="personal"><namePart type="given">H.J.</namePart><namePart type="family">Ehrlich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Muller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.M.</namePart><namePart type="family">Oh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.A.</namePart><namePart type="family">Tambyah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Joukhadar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Montomoli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Fisher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Berezuk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Fritsch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Low‐Baselli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Vartian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Bobrovsky</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.G.</namePart><namePart type="family">Pavlova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.M.</namePart><namePart type="family">Pollabauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Kistner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.N.</namePart><namePart type="family">Barrett</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low‐Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. (2008) A clinical trial of a whole‐virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573–84.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>358</number></detail><extent unit="pages"><start>2573</start><end>84</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>358</number></detail><extent unit="pages"><start>2573</start><end>84</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Immunogenicity, safety, and cross‐reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double‐blind, randomized trial</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.H.</namePart><namePart type="family">Fang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.T.</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.C.</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z.J.</namePart><namePart type="family">Feng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.G.</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.Z.</namePart><namePart type="family">Qiu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Lu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.S.</namePart><namePart type="family">Dong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Gao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.M.</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.D.</namePart><namePart type="family">Yin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.P.</namePart><namePart type="family">Dong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M., Wang N., Yin W.D., Dong X.P. (2009) Immunogenicity, safety, and cross‐reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double‐blind, randomized trial. Clin Infect Dis 48: 1087–95.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1087</start><end>95</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1087</start><end>95</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study</title></titleInfo><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Stephenson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.G.</namePart><namePart type="family">Das</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Wood</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Katz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stephenson I., Das R.G., Wood J.M., Katz J.M. (2007) Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25: 4056–63.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>4056</start><end>63</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>4056</start><end>63</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Characterization of a whole, inactivated influenza (H5N1) vaccine</title></titleInfo><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Tada</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tada Y. (2008) Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2: 261–6.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>261</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Influenza Other Respi Viruses</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>261</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild‐type virus strain induces cross‐protective immune responses</title></titleInfo><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Kistner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.K.</namePart><namePart type="family">Howard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Spruth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Wodal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Bruhl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Gerencer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.A.</namePart><namePart type="family">Crowe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Savidis‐Dacho</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Livey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Reiter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Mayerhofer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Tauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Grillberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Mundt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.G.</namePart><namePart type="family">Falkner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.N.</namePart><namePart type="family">Barrett</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kistner O., Howard M.K., Spruth M., Wodal W., Bruhl P., Gerencer M., Crowe B.A., Savidis‐Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., Mundt W., Falkner F.G., Barrett P.N. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild‐type virus strain induces cross‐protective immune responses. Vaccine 25: 6028–36.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>6028</start><end>36</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>6028</start><end>36</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity</title></titleInfo><name type="personal"><namePart type="given">F.L.</namePart><namePart type="family">Ruben</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.G.</namePart><namePart type="family">Jackson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruben F.L., Jackson G.G. (1972) A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 125: 656–64.</note><part><date>1972</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>656</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>1972</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>656</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Fisch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Cadilhac</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Vidor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Prazuck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Dublanchet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Lafaix</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fisch A., Cadilhac P., Vidor E., Prazuck T., Dublanchet A., Lafaix C. (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14: 1132–6.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1132</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1132</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Studies on a Hib‐tetanus toxoid conjugate vaccine: effects of co‐administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine</title></titleInfo><name type="personal"><namePart type="given">R.M.</namePart><namePart type="family">Carlsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.A.</namePart><namePart type="family">Claesson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Kayhty</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U.</namePart><namePart type="family">Selstam</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Iwarson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carlsson R.M., Claesson B.A., Kayhty H., Selstam U., Iwarson S. (1999) Studies on a Hib‐tetanus toxoid conjugate vaccine: effects of co‐administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine 18: 468–78.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>468</start><end>78</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>468</start><end>78</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Mark</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.M.</namePart><namePart type="family">Carlsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Granstrom</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mark A., Carlsson R.M., Granstrom M. (1999) Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 17: 2067–72.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>2067</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>2067</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Serum antibody responses after intradermal vaccination against influenza</title></titleInfo><name type="personal"><namePart type="given">R.B.</namePart><namePart type="family">Belshe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.K.</namePart><namePart type="family">Newman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Cannon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Duane</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Van Hoecke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.J.</namePart><namePart type="family">Howe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Dubin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., Howe B.J., Dubin G. (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351: 2286–94.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>351</number></detail><extent unit="pages"><start>2286</start><end>94</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>351</number></detail><extent unit="pages"><start>2286</start><end>94</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>A Randomized, Open‐Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization with Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal (ID) or the Intramuscular (IM) Route Among Healthy Adults</title></titleInfo><name type="personal"><namePart type="given">R.A.</namePart><namePart type="family">Shital Patel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">El‐Sahly</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Cate</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Keitel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>other</genre><part><date>2007</date></part></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split‐virus influenza A (H5N1) vaccine in healthy adults</title></titleInfo><name type="personal"><namePart type="given">T.M.</namePart><namePart type="family">Nolan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.C.</namePart><namePart type="family">Richmond</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.V.</namePart><namePart type="family">Skeljo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Pearce</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Hartel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.T.</namePart><namePart type="family">Formica</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Hoschler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Bennet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Ryan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Papanaoum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.L.</namePart><namePart type="family">Basser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.C.</namePart><namePart type="family">Zambon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., Hoschler K., Bennet J., Ryan D., Papanaoum K., Basser R.L., Zambon M.C. (2008) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split‐virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26: 4160–7.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>4160</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>4160</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Antigen sparing and cross‐reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial</title></titleInfo><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Leroux‐Roels</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Borkowski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Vanwolleghem</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Drame</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Clement</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Hons</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Devaster</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Leroux‐Roels</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leroux‐Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., Devaster J.M., Leroux‐Roels G. (2007) Antigen sparing and cross‐reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580–9.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>370</number></detail><extent unit="pages"><start>580</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>370</number></detail><extent unit="pages"><start>580</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Safety and antigenicity of non‐adjuvanted and MF59‐adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza</title></titleInfo><name type="personal"><namePart type="given">K.G.</namePart><namePart type="family">Nicholson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.E.</namePart><namePart type="family">Colegate</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Podda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Stephenson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wood</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Ypma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.C.</namePart><namePart type="family">Zambon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M.C. (2001) Safety and antigenicity of non‐adjuvanted and MF59‐adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937–43.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1937</start><end>43</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1937</start><end>43</end></extent></part></relatedItem></relatedItem><identifier type="istex">D8C94B5A650C9D8C073F65103101A6486AC3A45E</identifier><identifier type="ark">ark:/67375/WNG-39NGXXSL-5</identifier><identifier type="DOI">10.1111/j.1348-0421.2009.00191.x</identifier><identifier type="ArticleID">MIM191</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2009 The Societies and Blackwell Publishing Asia Pty Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-39NGXXSL-5/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001109 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001109 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D8C94B5A650C9D8C073F65103101A6486AC3A45E
|texte= Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection
}}
| This area was generated with Dilib version V0.6.33. |  |